March 22, 2024Cancer Research

Selective IKZF2 Degrader PVTX-405 Inhibits Tumor Growth and Enhances Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

HDHarshil DhruvArysta LifeScience (France)DMDonna McEachernUniversity of Michigan LBLongchuan BaiUniversity of Michigan

Discussion

Member takes

Implication

Preclinical evaluation demonstrates selective degradation of IKZF2 by PVTX-405 in mouse models, suggesting potential to enhance immune checkpoint therapies.

Key Points

Targeted breakdown of IKZF2 reduces suppressive regulatory T-cells and boosts inflammatory interleukin-2 production in cellular assays.
A 6.3 nM half-maximal degradation concentration selectively degrades IKZF2 while sparing other cereblon neosubstrates across test models.
Preclinical evaluation using humanized cereblon mice with MC38 tumors tested daily oral dosing alone and with immune checkpoint therapies.
Pharmacological degradation of IKZF2 synergizes with anti-PD1 or anti-LAG3 treatments, but findings remain limited to animal models.

Cite This Study

Dhruv et al. (2024) studied this question.

synapsesocial.com/papers/68e72cdcb6db6435876a663d https://doi.org/10.1158/1538-7445.am2024-2656

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation demonstrates selective degradation of IKZF2 by PVTX-405 in mouse models, suggesting potential to enhance immune checkpoint therapies.

Selective IKZF2 Degrader PVTX-405 Inhibits Tumor Growth and Enhances Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Selective IKZF2 Degrader PVTX-405 Inhibits Tumor Growth and Enhances Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider